Perindopril Tablets

Perindopril is one of the most prescribed ACE inhibitors in the UK, used across a range of cardiovascular conditions in primary and specialist care. Perindopril tablets are a prescription-only antihypertensive medication belonging to the ACE inhibitor class. They are used for hypertension treatment, symptomatic heart failure, and reduction of cardiovascular risk in adults with stable coronary artery disease. As part of cardiovascular therapy, Perindopril acts on the renin-angiotensin system to lower blood pressure and protect the heart and kidneys over time. A prescription can only be issued following a clinical consultation.

Perindopril tablets are an oral prescription medicine containing Perindopril as the active ingredient. Perindopril is an ACE inhibitor that is available in the UK in two different salt forms: Perindopril erbumine (2 mg, 4 mg, 8 mg) and Perindopril arginine (2.5 mg, 5 mg, 10 mg). These two formulations are not interchangeable at the same numerical dose. This service provides Perindopril erbumine tablets. If you are switching between suppliers or brands, check with your pharmacist that you are receiving the same salt form and equivalent dose.

Perindopril is licensed in the UK for three indications. First, the treatment of hypertension. Second, the treatment of symptomatic heart failure. Third, the reduction of cardiovascular events in patients with stable coronary artery disease. This third indication, which is based on outcomes from the EUROPA clinical trial, means Perindopril may be prescribed for heart health and heart protection in patients who have had a heart attack or have established coronary artery disease, even if their blood pressure is not elevated.

Perindopril is a prodrug. After absorption, it is converted by the liver to perindoprilat, the active form that exerts the ACE inhibiting effect. This conversion requires adequate hepatic function, which is a consideration in patients with significant liver disease.

Perindopril lowers blood pressure and provides cardiovascular protection by acting on the renin-angiotensin system.

The Renin-Angiotensin System

The renin-angiotensin system regulates blood pressure through a hormonal cascade. The kidneys release renin in response to low blood pressure. Renin converts angiotensinogen to angiotensin I, which is then converted by ACE to angiotensin II. Angiotensin II causes blood vessels to narrow and signals the body to retain sodium and water, both raising blood pressure. Over time, sustained angiotensin II activity contributes to organ damage in the heart, kidneys, and blood vessels.

ACE Inhibition by Perindoprilat

Perindoprilat, the active form of perindopril, blocks the ACE enzyme. This prevents the conversion of angiotensin I to angiotensin II. Without angiotensin II, blood vessels remain relaxed and sodium retention is reduced. Blood pressure falls as a result. Perindopril also reduces the breakdown of bradykinin, which causes additional vasodilation but is also responsible for the dry cough side effect associated with the ACE inhibitor class.

The reduction in workload on the heart from lower blood pressure and reduced vascular resistance is the basis for perindopril's use in heart failure and coronary artery disease. In patients with stable coronary artery disease, Perindopril reduces the risk of cardiovascular events including heart attack and stroke, independently of its blood pressure lowering effect, through mechanisms including improved endothelial function and reduced arterial stiffness.

Always take Perindopril exactly as your prescriber instructs. The information below summarises key points from the current UK SmPC. Read the Patient Information Leaflet supplied with your medicine before starting treatment.

• Take Perindopril once daily, in the morning before a meal. The SmPC for Perindopril erbumine specifically recommends taking the tablet before eating, as food reduces the conversion of Perindopril to the active perindoprilat.
• Swallow the tablet whole with a glass of water.
• If you miss a dose, take it as soon as you remember on the same day. If you only remember the following day, skip the missed dose and continue with your normal schedule. Do not take two doses on the same day.
• Do not stop taking Perindopril without speaking to your prescriber first. Stopping treatment can cause blood pressure to rise again or worsen heart failure symptoms.
• Your prescriber will typically start you at a low dose and increase it over several weeks based on your blood pressure response, kidney function, and potassium levels. First-dose hypotension is a known risk with ACE inhibitors, particularly in patients who are dehydrated, on diuretics, or have heart failure. Your prescriber will manage this through dose titration and monitoring. Attend all follow up appointments to allow safe and effective dose adjustment.

Perindopril erbumine tablets are available in three strengths. The appropriate dose depends on the indication being treated and your individual clinical response.

Perindopril 2 mg Tablets

The 2 mg tablet is the lowest available strength. For hypertension, a starting dose of 4 mg is standard for most patients, but 2 mg may be used when extra caution is needed, such as in elderly patients, those with kidney impairment, or those at risk of a first dose blood pressure drop. For heart failure, dosing typically begins at 2 mg once daily and is increased gradually under close supervision. The 2 mg strength allows careful initial titration.

Perindopril 4 mg Tablets

The 4 mg tablet is the standard starting and maintenance dose for hypertension in most adults. Many patients will achieve adequate blood pressure control at 4 mg once daily. If blood pressure is not adequately controlled after one month, the dose may be increased to 8 mg. For stable coronary artery disease, the target dose is 8 mg once daily, reached by starting at 4 mg and increasing after two weeks, as tolerated.

Perindopril 8 mg Tablets

The 8 mg tablet is the maximum dose for Perindopril erbumine. It is used in patients whose blood pressure is not adequately controlled at 4 mg, and as the target maintenance dose in patients with stable coronary artery disease. For heart failure, the maximum dose reached through titration is typically 4 mg once daily, though individual protocols may vary. All dose decisions are made by your prescriber. Do not change your dose without medical advice.

Like all medicines, Perindopril can cause side effects. The information below is based on the current UK SmPC. Refer to the Patient Information Leaflet for the full list.

Common Side Effects (may affect up to 1 in 10 people)

• Dry, persistent cough. This is the most frequently reported side effect of Perindopril and is a class effect of all ACE inhibitors. It results from bradykinin accumulation. The cough can occur at any time during treatment. If troublesome, speak to your prescriber, who may consider switching to an ARB.
• Dizziness or lightheadedness, particularly on standing. More likely at the start of treatment or after a dose increase.
• Headache
• Fatigue

Uncommon Side Effects (may affect up to 1 in 100 people)

• Nausea, vomiting, or diarrhoea
• Raised blood potassium (hyperkalaemia)
• Changes in kidney function, particularly in patients with pre existing kidney disease or reduced blood supply to the kidneys
• Skin rash or itching

Serious Side Effects: Seek Urgent Medical Attention

Go to your nearest accident and emergency department or call 999 immediately if you experience:

• Angioedema: sudden swelling of the face, lips, tongue, or throat. This is rare but potentially life threatening and is a class effect of ACE inhibitors. It can occur at any time during treatment. Throat angioedema can obstruct breathing and requires immediate emergency medical care. If you have had angioedema from any ACE inhibitor, you must not take perindopril.
• Signs of severely raised potassium such as muscle weakness, irregular heartbeat, or confusion
• A significant fall in urine output, which may indicate acute kidney injury

Report any suspected side effect to your prescriber, pharmacist, or via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Perindopril Tablets May Be Suitable If You:

• Are an adult with a confirmed diagnosis of hypertension
• Have symptomatic heart failure and are receiving conventional therapy
• Have stable coronary artery disease and your prescriber has determined that cardiovascular risk reduction with an ACE inhibitor is appropriate
• Are already prescribed Perindopril erbumine and require a repeat prescription through an online prescribing service

Perindopril Tablets Are Not Suitable If You:

• Are pregnant or planning to become pregnant. Perindopril is contraindicated in pregnancy. ACE inhibitors cause serious harm to the developing baby, particularly in the second and third trimesters, including kidney damage and foetal death. Contact your prescriber immediately if you become pregnant while taking perindopril.
• Are breastfeeding
• Have a history of angioedema related to previous ACE inhibitor treatment, or hereditary or idiopathic angioedema
• Have severe kidney impairment or are on dialysis
• Have significant liver disease. Perindopril requires hepatic conversion to its active form.
• Are taking aliskiren and have diabetes or moderate to severe kidney impairment
• Have a known allergy or hypersensitivity to perindopril, any other ACE inhibitor, or any excipient listed in the SmPC
• Are under 18 years of age

Tell your prescriber about all medicines you take. The following interactions are of particular clinical importance for perindopril:

• Potassium supplements, potassium-sparing diuretics (such as spironolactone or amiloride), and potassium-containing salt substitutes: these can raise blood potassium to dangerous levels when combined with perindopril.
• NSAIDs such as ibuprofen: regular use can reduce the blood pressure lowering effect of Perindopril and increase the risk of kidney problems.
• Lithium: ACE inhibitors increase lithium blood levels. Close monitoring is required if both medicines are used together.
• Diuretics: combining Perindopril with a diuretic can cause a significant first dose blood pressure drop, particularly in patients who are volume depleted. Your prescriber will manage this carefully.
• Aliskiren: contraindicated in combination with Perindopril in patients with diabetes or significant kidney impairment.
• Insulin and oral antidiabetic medicines: ACE inhibitors may enhance the blood glucose lowering effect. Patients with diabetes should monitor blood glucose carefully, particularly when starting perindopril.

Your prescriber will review all current medicines during the clinical assessment before any prescription is considered.

Perindopril is a Prescription Only Medicine. The clinical consultation is the essential first step. A prescription will only be issued if a registered prescriber concludes, based on their individual assessment of your circumstances, that Perindopril is clinically appropriate for you.

During your online consultation with Pharmacy Planet, a registered prescriber will review the information you provide. This includes your diagnosis, blood pressure history, cardiac history, kidney function where available, current medicines, and any other relevant medical information. The prescriber will assess whether Perindopril erbumine is the right choice, which strength is appropriate, and whether the online service is suitable for your individual situation.

Not all consultations will result in a prescription. The prescriber may request recent blood test results or recommend a different medicine. This is particularly relevant for patients with heart failure or coronary artery disease, where treatment complexity often warrants in-person care. This process is designed to protect your safety.

If you are under the care of your GP, a cardiologist, or a heart failure specialist, please keep them informed of all medicines prescribed through online services. Coordinated care supports the safest approach to BP regulation, heart health, and long term cardiovascular therapy.

• Store below 30°C.
• Store in the original packaging to protect from moisture.
• Keep out of the sight and reach of children.
• Do not use after the expiry date printed on the packaging.
• Do not dispose of medicines via household waste or wastewater. Return unused or out of date tablets to your pharmacist for safe disposal.
• Full storage instructions are provided in the Patient Information Leaflet supplied with your medicine.

The table below compares commonly prescribed ACE inhibitor tablets and capsules available at Pharmacy Planet. All are prescription-only medicines that act on the renin-angiotensin system to lower blood pressure.

Important: This comparison is for general information only and does not replace medical advice. A prescriber will decide which treatment is suitable for you following an online consultation.

Pharmacy Planet is a GPhC-registered online pharmacy providing access to prescription medicines through a clinically led consultation process. Our registered prescribers and pharmacists are committed to patient safety, clinical accuracy, and responsible prescribing.

We follow GPhC standards, MHRA guidance, and ASA advertising regulations in all aspects of our service. Every prescription is reviewed and dispensed by qualified healthcare professionals. We provide clear, factual information to support patients in understanding their antihypertensive medication and making informed decisions about their BP regulation and cardiovascular therapy.

If you have questions about perindopril, heart health, or any other medicine, our pharmacy team is available to help. We are committed to transparent, patient centred care.

References

1. Electronic Medicines Compendium (eMC). Perindopril erbumine 2 mg, 4 mg and 8 mg tablets — Summary of Product Characteristics. https://www.medicines.org.uk/emc. Accessed May 2026.
2. National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline NG136. https://www.nice.org.uk/guidance/ng136. Accessed May 2026.
3. National Institute for Health and Care Excellence (NICE). Chronic heart failure in adults: diagnosis and management. NICE guideline NG106. https://www.nice.org.uk/guidance/ng106. Accessed May 2026.
4. NHS. Perindopril. https://www.nhs.uk/medicines/perindopril. Accessed May 2026.
5. Joint Formulary Committee. British National Formulary (BNF). Perindopril erbumine. BMJ Group and Pharmaceutical Press. https://bnf.nice.org.uk. Accessed May 2026.
6. Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card — report a side effect. https://yellowcard.mhra.gov.uk. Accessed May 2026.